Inventors:
Jincong Zhuo - Boothwyn PA, US
Meizhong Xu - Hockessin DE, US
Chunhong He - Boothwyn PA, US
Colin Zhang - Ambler PA, US
Ding-Quan Qian - Newark DE, US
David M. Burns - Philadelphia PA, US
Yun-Long Li - Chadds Ford PA, US
Brian Metcalf - Moraga CA, US
Wenqing Yao - Kennett Square PA, US
Assignee:
INCYTE CORPORATION - Wilmington DE
International Classification:
A61K 31/397, C07D 253/065, A61K 31/53, A61K 31/496, C12N 5/00, A61P 11/00, A61P 29/00, A61P 9/00, A61P 37/00, A61P 1/16, A61P 35/00, C12N 9/99, C07D 239/70, A61K 31/519
US Classification:
51421018, 544184, 514243, 544281, 5142591, 51425216, 435184, 435375
Abstract:
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.